XTL Biopharmaceuticals Lt... (XTLB)
NASDAQ: XTLB
· Real-Time Price · USD
1.18
0.01 (0.85%)
At close: Oct 03, 2025, 3:48 PM
1.17
-0.85%
After-hours: Oct 03, 2025, 04:00 PM EDT
XTL Biopharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 451K | 162K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 448K | 116K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 119K | 162K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -2.17M | -1.56M | -947K | -689K | -765K | -790K | -843K | -882K | -880K | -941K | -1.18M | -1.51M | -1.5M | -1.47M | -1.24M | -1.18M |
Interest Income | 34K | 158K | 154K | 154K | 156K | 30K | 21K | 17K | 8K | 8K | 8K | 8K | 5K | 5K | 5K | 25K |
Pretax Income | -1.16M | -1.06M | -718K | -378K | -1.78M | -2.25M | -2.85M | -2.77M | -1.35M | 1.5M | 1.81M | 1.23M | 1.01M | -884K | -964K | -1.03M |
Net Income | -1.03M | -1.06M | -718K | -378K | -1.78M | -2.25M | -2.85M | -2.77M | -1.35M | 1.5M | 1.81M | 1.23M | 1.01M | -884K | -964K | -1.03M |
Selling & General & Admin | 2.05M | 1.53M | 923K | 665K | 734K | 759K | 815K | 845K | 850K | 911K | 1.13M | 1.46M | 1.44M | 1.41M | 1.19M | 1.13M |
Research & Development | 98K | 72K | 24K | 24K | 31K | 31K | 28K | 37K | 30K | 30K | 45K | 48K | 54K | 60K | 54K | 50K |
Other Expenses | 147K | 116K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 2.29M | 1.72M | 947K | 689K | 765K | 790K | 843K | 882K | 880K | 941K | 1.18M | 1.51M | 1.5M | 1.47M | 1.24M | 1.18M |
Interest Expense | 86K | 122K | 57K | 76K | 85K | 85K | 57K | 36K | 20K | 20K | 20K | 23K | 14K | 14K | 14K | 9K |
Selling & Marketing Expenses | 178K | 284K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.62M | 1.72M | 947K | 689K | 765K | 790K | 843K | 882K | 880K | 941K | 1.18M | 1.51M | 1.5M | 1.47M | 1.24M | 1.18M |
Income Tax Expense | -130K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -9K | -3K | 6K | 6K | 3K | -3K | -12K |
Shares Outstanding (Basic) | 6.73M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.28M | 5.28M | 5.27M |
Shares Outstanding (Diluted) | 7.04M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.77M | 5.38M | 5.28M | 5.27M |
EPS (Basic) | -0.18 | -0.19 | -0.13 | -0.07 | -0.33 | -0.42 | -0.53 | -0.51 | -0.25 | 0.29 | 0.34 | 0.23 | 0.24 | -0.36 | -0.37 | -0.39 |
EPS (Diluted) | -0.18 | -0.19 | -0.13 | -0.07 | -0.33 | -0.42 | -0.53 | -0.51 | -0.25 | 0.26 | 0.32 | 0.21 | 0.22 | -0.35 | -0.37 | -0.39 |
EBITDA | -1.15M | -950K | -632K | -95K | -819K | -759.75K | -886.75K | -929.75K | -939.5K | -1M | -941.25K | -1.27M | -1.26M | -1.23M | -1.02M | -937.5K |
EBIT | -1.15M | -950K | -677K | -318K | -1.7M | -1.64M | -2.35M | -2.29M | -880K | -941K | 354K | -516K | -1.26M | -1.23M | -1.85M | -1.63M |
Depreciation & Amortization | 83.75K | 34K | -269.75K | 500.00 | 750.00 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 217.75K | 218K |